Global Rare Neurological Disease Treatment Market Size
Market for treatments for rare neurological diseases was valued at US$ 8931.49 million in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 7.50% to reach US$ 18367 million by 2030.
The market for treatments for rare neurological illnesses is expected to expand rapidly over the next several years, from 2020 to 2030. Growing awareness of these illnesses, improvements in neurobiology and healthcare, and quicker approvals of novel treatment modalities are all factors that will support the expansion of the worldwide market. Too many times, rare neurological disorders (RNDs) remain undiagnosed, and suitable treatment is frequently unavailable. Approximately 5-8 percent of Europeans suffer from one of the 5000–8000 rare diseases that exist, many of which have neurological symptoms. Reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Agnosia, Creutzfeldt-Jakob disease, Aicardi syndrome, and Aicardi-Goutieres syndrome are a few neurological conditions. But there are a number of obstacles to diagnosing rare neurological illnesses, such as a dearth of public understanding of uncommon neurological conditions. Globally, rare diseases are severely impacting both the healthcare system and the economy. For example, the National Organization for Rare Disorders (NORD) Report estimates that there are approximately 7,000 recognized rare diseases that affect 25 million Americans and significantly increase morbidity and mortality. Furthermore, approximately one-third of these are thought to have neurological components and symptoms. Governments everywhere are pushing for quicker advancement as rare neurological illnesses become more prevalent.